Latest Insider Transactions at Taysha Gene Therapies, Inc. (TSHA)
This section provides a real-time view of insider transactions for Taysha Gene Therapies, Inc. (TSHA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Taysha Gene Therapies, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Taysha Gene Therapies, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2021
|
Suyash Prasad CMO and Head of R&D |
SELL
Open market or private sale
|
Direct |
20,076
-1.06%
|
$441,672
$22.52 P/Share
|
|
Jun 29
2021
|
Suyash Prasad CMO and Head of R&D |
SELL
Open market or private sale
|
Direct |
39,218
-1.96%
|
$941,232
$24.46 P/Share
|
|
May 20
2021
|
Sean P. Nolan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,170
+50.0%
|
$25,740
$22.35 P/Share
|
|
May 14
2021
|
Paul B Manning |
BUY
Open market or private purchase
|
Direct |
12,000
+50.0%
|
$240,000
$20.98 P/Share
|
|
Sep 28
2020
|
Paul B Manning |
BUY
Conversion of derivative security
|
Indirect |
5,295,307
+33.53%
|
-
|
|
Sep 28
2020
|
Sukumar Nagendran President and Head of R&D |
BUY
Conversion of derivative security
|
Direct |
19,226
+50.0%
|
-
|
|
Sep 28
2020
|
Sean P. Nolan Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
1,091,101
+25.07%
|
-
|
|
Sep 28
2020
|
Suyash Prasad CMO and Head of R&D |
BUY
Conversion of derivative security
|
Direct |
3,844
+0.57%
|
-
|